Ali Farhoudian

Dr. Ali Farhoudian


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2020 in Basic and Clinical Neuroscience Journal
Verified
Journal Article
Open access
PDF file
AFAli Farhoudian
Ali Farhoudian
ABAlexander Baldacchino
Alexander Baldacchino
NCNicolas Clark
Nicolas Clark
GGGilberto Gerra
Gilberto Gerra
HEHamed Ekhtiari
Hamed Ekhtiari
EREmran Mohammad Razaghi
Emran Mohammad Razaghi
Coronavirus disease 2019 (COVID-19) is escalating all over the world and has higher morbidities and mortalities in certain vulnerable populations. People who use drugs (PWUD) are a marginalized and stigmatized group with weaker immunity responses, vulnerability to stress, poor health conditions, high-risk behaviors, and lower access to health care services. These ...

18 November 2019 in Addiction
Verified
Journal Article
Closed access
PDF file
HEHamed Ekhtiari
Hamed Ekhtiari
ANAlireza Noroozi
Alireza Noroozi
AFAli Farhoudian
Ali Farhoudian
SRSeyed Ramin Radfar
Seyed Ramin Radfar
AHAhmad Hajebi
Ahmad Hajebi
RRRichard Rawson
Richard Rawson

29 April 2021 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
SRSeyed Ramin Radfar
Seyed Ramin Radfar
CJCornelis A. J. De Jong
Cornelis A. J. De Jong
AFAli Farhoudian
Ali Farhoudian
MEMohsen Ebrahimi
Mohsen Ebrahimi
PRParnian Rafei
Parnian Rafei
ICISAM-PPIG Global Survey Consortium
ISAM-PPIG Global Survey Consortium
Background:The coronavirus disease 2019 (COVID-19) pandemic has impacted people with substance use disorders (SUDs) worldwide, and healthcare systems have reorganized their services in response to the pandemic.Methods:One week after the announcement of the COVID-19 as a pandemic, in a global survey, 177 addiction medicine professionals described COVID-19-related health responses in their own 77 countries in terms of SUD treatment and harm reduction services. The health responses were categorized around (1) managerial measures and systems, (2) logistics, (3) service providers, and (4) vulnerable groups.Results:Respondents from over 88% of countries reported that core medical and psychiatric care for SUDs had continued; however, only 56% of countries reported having had any business continuity plan, and 37.5% of countries reported shortages of methadone or buprenorphine supplies. Participants of 41% of countries reported partial discontinuation of harm-reduction services such as needle and syringe programs and condom distribution. Fifty-seven percent of overdose prevention interventions and 81% of outreach services were also negatively impacted.Conclusions:Participants reported that SUD treatment and harm-reduction services had been significantly impacted globally early during the COVID-19 pandemic. Based on our findings, we highlight several issues and complications resulting from the pandemic concerning people with SUDs that should be tackled more efficiently during the future waves or similar pandemics. The issues and potential strategies comprise the following: (1) helping policymakers to generate business continuity plans, (2) maintaining the use of evidence-based interventions for people with SUDs, (3) being prepared for adequate medication supplies, (4) integrating harm reduction programs with other treatment modalities, and (5) having specific considerations for vulnerable groups such as immigrants and refugees.

21 July 2020 in medRxiv
Verified
Preprint
Open access
PDF file
AFAli Farhoudian
Ali Farhoudian
SRSeyed Ramin Radfar
Seyed Ramin Radfar
HAHossein Mohaddes Ardabili
Hossein Mohaddes Ardabili
PRParnian Rafei
Parnian Rafei
MEMohsen Ebrahimi
Mohsen Ebrahimi
HEHamed Ekhtiari
Hamed Ekhtiari
Background and aims: COVID-19 has infected more than 13 million people worldwide and impacted the lives of many more, with a particularly devastating impact on vulnerable populations, including people with substance use disorders (SUDs). Quarantines, travel bans, regulatory changes, social distancing and ‘lockdown’ measures have affected drug and alcohol supply chains and subsequently their availability, price and use patterns, with possible downstream effects on presentations of SUDs and demand for treatment. Given the lack of multicentric epidemiologic studies, we conducted a rapid global survey within the International Society of Addiction Medicine (ISAM) network in order to understand the status of substance-use patterns during the current pandemic. Design: Cross-sectional survey. Setting: Worldwide. Participants: Starting on April 4 th , 2020 during a 5-week period, the survey received 185 responses from 77 countries. Measurements: To assess addiction medicine professionals’ perceived changes in drug and alcohol supply, price, use pattern and related complications during the COVID-19 pandemic. Findings: Participants reported (among who answered “decreased” or “increased”, percentage of those who were in majority is reported in the parenthesis) a decrease in drug supply (69.0%), and at the same time an increase in price (95.3%) globally. With respect to changes in use patterns, an increase in alcohol (71.7%), cannabis (63.0%), prescription opioids (70.9%), and sedative/hypnotics (84.6%) use was reported while the use of amphetamines (59.7%), cocaine (67.5%), and opiates (58.2%) was reported to decrease overall. Conclusions: The global report on changes in the availability, use patterns and complications of alcohol and drugs during the COVID-19 pandemic should be considered in making new policies and in developing mitigating measures and guidelines during the current pandemic (and probable future ones) in order to minimize risks to SUDs. Competing interest: Authors claimed no competing interest

30 April 2019 in Iranian Rehabilitation Journal
Verified
Journal Article
Open access
OMOmid Massah
Omid Massah
HRHassan Rafiey
Hassan Rafiey
SSSchwann Shariatirad
Schwann Shariatirad
SRSeyed Ramin Radfar
Seyed Ramin Radfar
EAElaheh Ahounbar
Elaheh Ahounbar
AFAli Farhoudian
Ali Farhoudian

1 September 2014 in Alcohol and Alcoholism
Verified
Journal Article
Open access
PDF file
PSP. Shirinbayan
P. Shirinbayan
HRH. Rafiey
H. Rafiey
ARA. V. Roshan
A. V. Roshan
HNH. Narenjiha
H. Narenjiha
AFAli Farhoudian
Ali Farhoudian
ADA. Dadkhah
A. Dadkhah
In the methadone maintenance therapy (MMT) as the treatment of choice in opiate dependency, retention is considered as a target. Given the paucity of data regarding factors affecting retention in MMT in Iran, we sought to determine the predictors of duration of retention. This multi-center prospective study was conducted at 7 outpatient treatment facilities in 4 cities in Iran, in 2007. 282 consecutive opiate dependent people were followed for 6 months, following their entry to MMT. Independent data were registered at baseline and included socio-demographic, social, psychological, drug related and legal data. Length of retention in MMT (0 -6) considered as dependent variable. Predictors of length of retention were determined using a backward linear regression model. Retention was 0 months in 17.7% (n = 50), 1 months in 19.8% (n = 56), 2 months in 9.2% (n = 26), 3 months in 3.5% (n = 10), 4 months in 8.2% (n = 23), 5 months in 18.8% (n = 53) and 6 months in 22.7% (n = 64). According to the backward linear regression, the only predictors of remission were city (B = 0.427, p < 0.001, CI = 0.339 -0.514), perceived importance of distance to clinic (B = -0.008, p = 0.085, CI = -0.018 -0.001), perceived social support (B = 0.006, p= 0.069, CI = 0.000 -0.013), and perceived pleasure with drug use (B = 0.010, p = 0.007, CI = 0.003 -0.017). This study shed light on factors that may serve as barriers for remaining in MMT for opiate dependence, in Iran. Some variables should be considered in programs developed by Iranian authorities to increase retention rate in MMT.